This ‘Primary Sclerosing Cholangitis (PSC) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of Primary Sclerosing Cholangitis (PSC) historical and forecasted epidemiology in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan.
The disease epidemiology covered in the report provides historical as well as forecasted Primary Sclerosing Cholangitis (PSC) epidemiology segmented as the total diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC), gender-specific cases of Primary Sclerosing Cholangitis (PSC), comorbidity-specific cases of Primary Sclerosing Cholangitis (PSC), symptom-specific cases of Primary Sclerosing Cholangitis (PSC). The report includes the diagnosed prevalent cases scenario of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan from 2019 to 2032.
The diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC) associated in the 7MM + Nordic countries were approximately 59,000 in 2021.
Primary Sclerosing Cholangitis (PSC) Disease Understanding
Primary sclerosing cholangitis (PSC) is a chronic disease that slowly damages the bile ducts. In PSC patients, the bile ducts are blocked due to inflammation and scarring or fibrosis, leading to the accumulation of bile in the liver, which gradually damages liver cells and causes cirrhosis or fibrosis of the liver. As cirrhosis progresses and the amount of scar tissue in the liver increases, the liver slowly loses its functionality. The scar tissue may block the drainage of the bile ducts leading to bile infection.Primary Sclerosing Cholangitis (PSC) Epidemiology
The Primary Sclerosing Cholangitis (PSC) epidemiology division provides insights into the historical and prevalent patient pool, along with the forecasted trend for all the seven major countries + Nordic countries. It recognizes the causes of current and forecasted trends by exploring numerous studies and views of KOL. The report also provides the diagnosed patient pool, trends, and assumptions.Key Findings
The total diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC) patients in the 7MM + Nordic countries are increasing during the study period, i.e., 2019-2032.The disease epidemiology covered in the report provides historical as well as forecasted Primary Sclerosing Cholangitis (PSC) epidemiology segmented as the total diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC), gender-specific cases of Primary Sclerosing Cholangitis (PSC), comorbidity-specific cases of Primary Sclerosing Cholangitis (PSC), symptom-specific cases of Primary Sclerosing Cholangitis (PSC). The report includes the diagnosed prevalent cases scenario of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan from 2019 to 2032.
Country-wise Primary Sclerosing Cholangitis (PSC) Epidemiology
The epidemiology segment also provides the Primary Sclerosing Cholangitis (PSC) epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan.The diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC) associated in the 7MM + Nordic countries were approximately 59,000 in 2021.
- As per the estimates, the United States has the largest diagnosed prevalent population of Primary Sclerosing Cholangitis (PSC)
- Among the EU-5 countries, Germany had the highest diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC), followed by France. On the other hand, Spain had the lowest diagnosed prevalent cases, with around 100 cases in 2021
- Sweden had the highest diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC) among Nordic countries, followed by Finland. On the other hand, Norway had the lowest diagnosed prevalent cases, with around 900 cases in 2021
Scope of the Report
- The Primary Sclerosing Cholangitis (PSC) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
- The Primary Sclerosing Cholangitis (PSC) epidemiology report and model provide an overview of Primary Sclerosing Cholangitis (PSC)' risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) + Nordic countries (Sweden, Finland, Denmark, and Norway)
- The report provides insight into Primary Sclerosing Cholangitis (PSC)' historical and forecasted patient pool in the seven major markets along with Nordic countries covering the United States, the EU-5 (Germany, Spain, France, Italy, UK), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan
- The report helps to recognize the growth opportunities in the 7MM + Nordic countries concerning the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Primary Sclerosing Cholangitis (PSC)
- The report provides the segmentation of the Primary Sclerosing Cholangitis (PSC) epidemiology by the diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries
- The report provides the Primary Sclerosing Cholangitis (PSC) epidemiology segmentation by gender-specific cases of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries
- The report provides the Primary Sclerosing Cholangitis (PSC) epidemiology segmentation by comorbidity-specific cases of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries
- The report provides the Primary Sclerosing Cholangitis (PSC) epidemiology segmentation by symptom-specific cases of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries
Report Highlights
- 11-year Forecast of Primary Sclerosing Cholangitis (PSC) Epidemiology
- 7MM + Nordic countries Coverage
- Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC)
- Gender-specific cases of Primary Sclerosing Cholangitis (PSC)
- Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC)
- Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC)
KOL Views
The publisher interviews KOLs, and SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.Key Questions Answered
- What are the major factors that will drive the change in the patient population in Primary Sclerosing Cholangitis (PSC) during the forecast period (2019-2032)?
- What are the key findings of the Primary Sclerosing Cholangitis (PSC) epidemiology across the 7MM + Nordic countries, and which country will have the highest number of patients during the forecast period (2019-2032)?
- What would be the total number of Primary Sclerosing Cholangitis (PSC) patients across the 7MM + Nordic countries during the forecast period (2019-2032)?
- Among the EU-5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in the 7MM + Nordic countries during the forecast period (2019-2032)?
- What are the disease risks, burdens, and unmet needs of the Primary Sclerosing Cholangitis (PSC) market?
- What are the current treatment patterns for Primary Sclerosing Cholangitis (PSC)?
Reasons to Buy
The Primary Sclerosing Cholangitis (PSC) epidemiology report will allow the user to- Develop business strategies by understanding the trends shaping and driving the global Primary Sclerosing Cholangitis (PSC) market
- Quantify patient populations in the global Primary Sclerosing Cholangitis (PSC) market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Primary Sclerosing Cholangitis (PSC) therapeutics in each market covered
- Understand the magnitude of the Primary Sclerosing Cholangitis (PSC) population by its diagnosed prevalence
- Understand the magnitude of the Primary Sclerosing Cholangitis (PSC) population by its Gender-specific cases
- Understand the magnitude of the Primary Sclerosing Cholangitis (PSC) population by its Comorbidity-specific cases
- Understand the magnitude of the Primary Sclerosing Cholangitis (PSC) population by its Symptom-specific cases
- The Primary Sclerosing Cholangitis (PSC) epidemiology report and model were written and developed by Master and PhD level epidemiologists
- The Primary Sclerosing Cholangitis (PSC) epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
Key Assessments
- Patient segmentation
- Disease risk and burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Nordic countries (Sweden, Finland, Denmark, and Norway)
- Japan
Table of Contents
1. Key Insights2. Report Introduction4. Executive Summary of Primary Sclerosing Cholangitis (PSC)7. Patient Journey8. KOL Views9. Acronyms and Abbreviations11. Publisher Capabilities12. Disclaimer13. About the Publisher
3. Primary Sclerosing Cholangitis (PSC) Epidemiology Overview at a Glance
5. Disease Background and Overview
6. Epidemiology and Patient Population
10. Appendix
List of Tables
List of Figures
